4A case for a racial justice agenda in treatment and research By Kenyon Farrow The Tuskegee Syphilis study remains a primary citation in both the scientific literature and popular conversations to explain the reluctance of African Americans to engage with…
Upholding narratives of Black science and treatment activism, and community mobilization in HIV/AIDS and TB By Suraj Madoori In February 2016, startling data released by the Centers for Disease Control and Prevention (CDC) at the Conference of Retroviruses and Opportunistic…
Pharma’s Obligations Under the Right to Science By Erica Lessem and Brian Citro Benefitting from scientific progress is a human right, but who’s responsible for ensuring that this right is upheld? As Mike Frick clearly lays out in “Science and…
Using human rights to strengthen TB research and access By Mike Frick Editor’s note: The following is based on the transcript of a plenary address delivered by the author at TB2016, a two-day TB conference held before the July International…
By Tim Horn Maximizing HIV, tuberculosis (TB), and viral hepatitis outcomes depends on the availability of state-of-the-art diagnostic and prognostic tools, engagement in expert and supportive care, and access to safe and effective drugs. Numerous technical barriers to these core…
Generic treatments for HIV, viral hepatitis, and cancer can be affordably—and profitably—mass-produced for broad, unobstructed availability By Tracy Swan TAG talks with Andrew Hill, senior visiting research fellow in the University of Liverpool’s Department of Pharmacology, about his group’s work…
A number of barriers to pre-exposure prophylaxis (PrEP) uptake, use, and adherence have been identified—cost shouldn’t be one of them By James Krellenstein and Jeremiah Johnson On July 16, 2012, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences’…
The story of U.S. drug pricing run amok isn’t just about corporate arrogance and avarice—it is also about government permissiveness and inaction By Tim Horn, Erica Lessem, and Kenyon Farrow On December 1, 2015, the U.S. Senate Finance Committee issued…
By Tim Horn The way I see it, you can go down in history as the poster boy for greedy drug-company executives, or you can change the system—yeah, you. —U.S. Representative Elijah E. Cummings (D-MD) With these words, directed at…
